Personalized chemo boosts CAR T-Cell success in young leukemia patients

NCT ID NCT07223021

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assigned to receive either standard or personalized fludarabine dosing. The goal is to see if the personalized approach extends the time without cancer returning or worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Baylor College Medical Center (Data Collection Only)
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Children's Hospital of Philadelphia (Data Collection Only)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital Medical Center (Data Collection Only)
RECRUITING

Cincinnati, Ohio, 45229, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Texas Children's Hospital (Data Collection)
NOT_YET_RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.